Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.
PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.
Hair loss treatments like finasteride, minoxidil, and hair transplants are more accessible and effective now. Concerns about side effects and skepticism about new treatments like hair cloning and GT20029 remain.
Hair loss significantly affects men's confidence and mental health. Common treatments include finasteride, dutasteride, and minoxidil, with some considering hair transplants.
PP405 is in a phase 3 trial for hair loss treatment, with the study expected to run until June 2028. Minoxidil and finasteride remain key treatments, with hopes for PP405 to offer a new mechanism of action.
Some individuals do not respond to oral minoxidil for hair loss, despite it generally working by improving blood flow to hair follicles. Factors like metabolism, drug interactions, and individual variations in the drug's activation may influence its effectiveness.
AI advancements, like AlphaFold, are speeding up drug discovery for hair loss, promising more effective treatments. Current options like minoxidil and finasteride have limitations, but new developments could improve solutions in 5-10 years.
A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.
The conversation discusses a hair loss and scalp care routine involving ciclopirox shampoo, benzoyl peroxide, clindamycin gel, clobetasol propionate, and calcipotriol to manage seborrheic dermatitis, folliculitis, and inflammation. It also touches on the role of diet and other treatments like oral minoxidil and pioglitazone for scalp health.
A study that outlines the full model for androgenic alopecia (AGA) which links DHT to cellular senescence in dermal papilla cells, and suggests black chokeberry as a source of cyanidin 3-O-arabinoside polyphenol with potential anti-oxidant properties that could reverse this process. The post encourages reaching out to experts in anti-aging and longevity to research treatments involving the polyphenol.
Hair loss may be influenced more by inflammation, microbiome imbalances, and gut health than DHT. Treatments discussed include minoxidil, finasteride, RU58841, fecal microbiota transplants, and JAK inhibitors.
New hair loss treatments include lab-grown hair cloning, scarless healing with verteporfin, GT20029 for receptor degradation, JAK inhibitors for follicle activation, and dermal papilla stem cell exosomes. These aim to regenerate hair rather than just slow hair loss.
PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.
Curved hair transplantation requires specialized tools and techniques to avoid damaging hair follicles, with modified FUE being the preferred method. Proper extraction and implantation angles are crucial to prevent complications like keloids and sterile folliculitis.
The conversation covers aggressive hair regrowth treatments like Dutasteride, Minoxidil (oral and topical), RU58841, microneedling, and ketoconazole shampoo. It also mentions PRP, laser therapy, GHK-Cu injections, and hormone therapy for maximum regrowth.
The user is experiencing hair loss and confusion over conflicting medical advice, with treatments including minoxidil, finasteride, and topical corticosteroids. They are unsure about the necessity of a biopsy and the timing of using minoxidil, while also considering the impact of potential androgenetic alopecia and telogen effluvium.
RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.
A user shared their year-long hair loss treatment using minoxidil, microneedling, and scalp massages, reporting moderate hair growth and stabilization. They suggest starting early with less harmful methods and consider adding finasteride or dutasteride if needed.
Treatments for hair loss, including finasteride, dutasteride, minoxidil, ketoconazole, microneedling, and low level laser light therapy, which aim to reduce DHT production, increase cell absorption and blood flow, and stimulate epidermal stem cells. It also stresses the importance of patience when using these treatments.
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.
A user experienced significant hair shedding and thinning 10 months post-hair transplant despite using minoxidil and topical finasteride. They are considering switching to oral finasteride or dutasteride and are also dealing with scalp conditions like seborrheic dermatitis.
Promising hair loss treatments in 2026 include GT20029, a topical androgen receptor degrader, and VDPHL01, an extended-release oral minoxidil, both offering safer alternatives with fewer side effects. Other treatments like sublingual minoxidil, OND-1, JW0061, TDM-105795, and AMP-303 are also being explored.
Scalp tension from the occipitalis muscle is theorized to contribute to hair loss, but most believe DHT and genetics are the main causes. Treatments like finasteride and minoxidil are considered more effective than addressing scalp tension.
Hair loss is linked to DHT, with treatments like finasteride and minoxidil being common but not definitive. Economic interests influence research, and there is potential for new treatments like PP405 and RU58841.
PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.
Increased Malassezia and Cutibacterium in the scalp microbiome are linked to higher sebum production and inflammation in androgenetic alopecia (AGA). Treatments include ciclopirox shampoo, benzoyl peroxide shampoo, clobetasol propionate, calcipotriol, minoxidil, finasteride, and dutasteride.
Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
Microneedling for hair restoration involves daily use of a 0.3 mm device and weekly use of a 0.5 mm device. Combining microneedling with Minoxidil can enhance hair growth.